ValuEngine Upgrades Dr.Reddy’s Laboratories (NYSE:RDY) to “Sell”

ValuEngine upgraded shares of Dr.Reddy’s Laboratories (NYSE:RDY) from a strong sell rating to a sell rating in a research report report published on Tuesday morning, ValuEngine reports.

A number of other brokerages have also issued reports on RDY. Credit Suisse Group upgraded Dr.Reddy’s Laboratories from an underperform rating to an outperform rating in a research report on Wednesday, September 4th. TheStreet upgraded Dr.Reddy’s Laboratories from a c rating to a b- rating in a report on Thursday, August 15th. Finally, Bank of America cut shares of Dr.Reddy’s Laboratories from a buy rating to a neutral rating in a research note on Monday, November 4th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the company’s stock. Dr.Reddy’s Laboratories currently has a consensus rating of Hold and a consensus target price of $39.50.

RDY opened at $39.99 on Tuesday. The company has a market cap of $6.63 billion, a PE ratio of 24.38 and a beta of 0.20. Dr.Reddy’s Laboratories has a twelve month low of $34.67 and a twelve month high of $42.82. The company has a 50-day moving average price of $39.52 and a 200 day moving average price of $37.93. The company has a quick ratio of 1.39, a current ratio of 1.96 and a debt-to-equity ratio of 0.10.

Dr.Reddy’s Laboratories (NYSE:RDY) last posted its quarterly earnings data on Friday, November 1st. The company reported $0.93 EPS for the quarter. Dr.Reddy’s Laboratories had a return on equity of 18.44% and a net margin of 16.20%. The company had revenue of $680.00 million during the quarter. As a group, sell-side analysts expect that Dr.Reddy’s Laboratories will post 1.51 earnings per share for the current year.

Several institutional investors have recently modified their holdings of the company. Bank of New York Mellon Corp lifted its position in Dr.Reddy’s Laboratories by 20.1% during the second quarter. Bank of New York Mellon Corp now owns 27,401 shares of the company’s stock worth $1,027,000 after buying an additional 4,587 shares in the last quarter. Atria Investments LLC purchased a new position in shares of Dr.Reddy’s Laboratories during the 2nd quarter worth $171,000. Panagora Asset Management Inc. boosted its position in shares of Dr.Reddy’s Laboratories by 8.2% during the 2nd quarter. Panagora Asset Management Inc. now owns 116,084 shares of the company’s stock valued at $4,349,000 after acquiring an additional 8,836 shares during the last quarter. Bank of America Corp DE grew its holdings in shares of Dr.Reddy’s Laboratories by 1.0% in the second quarter. Bank of America Corp DE now owns 188,488 shares of the company’s stock valued at $7,062,000 after purchasing an additional 1,859 shares during the period. Finally, Marshall Wace North America L.P. purchased a new stake in shares of Dr.Reddy’s Laboratories in the second quarter valued at about $314,000. Institutional investors and hedge funds own 12.66% of the company’s stock.

About Dr.Reddy’s Laboratories

Dr. Reddy's Laboratories Limited operates as an integrated pharmaceutical company worldwide. It operates through three segments: Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Proprietary Products. The Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosage with therapeutic equivalence to branded formulations.

Read More: How to Invest in Growth Stocks

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Dr.Reddy`s Laboratories (NYSE:RDY)

Receive News & Ratings for Dr.Reddy's Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dr.Reddy's Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.



Comments


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit